Cerebrolysin

FPF 1070, Cerebrolysatum, porcine brain hydrolysate

The Ground Truth Score

four plain questions, never one number

Porcine brain extract with real RCT data in stroke and TBI, but evidence is thin for healthy-brain cognitive enhancement.

Bottom line

Cerebrolysin is a complex mixture of low-molecular-weight neuropeptides from porcine brain tissue, approved in 45+ countries for stroke and dementia, with multiple RCTs showing modest functional benefit in neurological injury, but the evidence for healthy-individual cognition is essentially zero and the Cochrane review called overall certainty low to very low.

Does the science back it?

BHuman-trial signal

Do real people feel it?

Real buzz

Is it safe?

CThinly characterized

Could it be placebo?

Likely placebo

Can you legally get it?

Approved abroadA medicine elsewhere, not here

Approved and prescribed as a medicine in other countries, but not by FDA. That is real evidence a regulator somewhere reviewed it, and it is worth weighing. It is not a US route, and it does not mean the version sold to you domestically is that same reviewed product.

Approved in 45+ countries for stroke and dementia, with multiple RCTs showing modest functional benefit in neurological injury. Not FDA-approved. Evidence for cognitive enhancement in healthy people is a different question, and much weaker.

Legal status as of 2026-06-16. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.

"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.

Why is the evidence this thin? It's mostly economics →

Dose at a glance

full dosing ↓

5-10 mL IM daily x 10-21 days, cycled 2-4x/year; clinical trials used 15-30 mL IV; no SubQ standard exists

Reported, not prescribed. Verify your vial and your math.

The gist

Real RCT data in stroke and TBI, but the primary functional independence endpoint did not reach significance and NIHSS improvement (1.39 points) sits below the clinically meaningful threshold.
The nootropic community uses it off-label for cognitive enhancement in healthy brains. Zero controlled evidence exists for that population.
The preclinical mechanistic foundation has a serious problem: multiple core papers were retracted in 2025 after NIH confirmed the lead researcher (Eliezer Masliah) fabricated data, and he was funded by the manufacturer.

First documented human use

1954, initial clinical approval in Austria for metabolic brain failure and TBI by EVER Neuro Pharma (formerly EBEWE)

CognitiveNeuroprotectionRecoveryTBI rehabilitation

Real talk

Here's the deal with Cerebrolysin. It has actual clinical trials, which puts it ahead of 90% of the peptides people are injecting, but the bar is lower than it looks. The stroke meta-analysis showed 1.39 points on the NIHSS, and the NINDS says you need 4+ for clinical meaningfulness. The functional independence endpoint flat-out did not reach significance. The nootropic community is self-injecting this stuff for healthy-brain cognitive enhancement with zero human evidence, stacking it with racetams, and attributing the result to the vial when it could be anything. What's actually gnarly is that the guy who built most of the preclinical mechanistic case was committing data fraud for decades while being funded by the manufacturer. That's not a footnote, that's a foundational crack. If you have a real neurological injury and a physician in the loop, the data is at least real. If you're healthy and running 10-day IM cycles for focus, the honest answer is: who the fuck knows.

The deep dive

The pitch

What people claim it does

Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.

Marketed as a neurotrophic factor mimetic that crosses the blood-brain barrier
Claimed to promote neuroplasticity and axonal sprouting after brain injury
Sold as a cognitive enhancer for healthy users at low IM doses
Promoted for Alzheimer's and vascular dementia as a disease-modifying adjunct
Claimed to reduce neuroinflammation and apoptosis via BDNF/NGF pathway activation

The data behind each bullet

What actually backs it

Improves functional recovery after acute ischemic stroke

Meta-analysis of 14 RCTs (N=2,884) showed pooled NIHSS improvement of 1.39 points (95% CI 0.53-2.25). However, the primary functional independence endpoint (mRS 0-2) did NOT reach statistical significance (RR 1.31, 95% CI 0.90-1.91, p>0.05). The NIHSS minimum clinically important difference is typically defined as 4+ points by NINDS standards, so 1.39 points is sub-threshold for clinical meaningfulness at the individual level. Most trials were industry-funded.

PMC12465088 - Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials (2025) ↗

Improves outcomes in traumatic brain injury

2023 systematic review of 10 clinical studies (N=8,749) found statistically significant improvement in GCS and GOS scores. Mortality and length of stay were not affected. Multiple industry-sponsored trials limit certainty. Important limitation: only a subset of the 10 studies were blinded RCTs; the remainder were retrospective observational studies. The pooled N reflects the mixed design, not an RCT-only sample, which makes the B grade a ceiling rather than a floor for this claim.

PMC10046100 - Cerebrolysin in TBI: Systematic Review and Meta-Analysis, Brain Sciences 2023 ↗

Benefits Alzheimer's disease and vascular dementia

Cochrane review for vascular dementia (2019, 6 RCTs, N=597) found promising signals but rated evidence quality as low to very low. A 2023 Cochrane update on cerebrolysin for acute ischaemic stroke (pub7, CD007026) found no evidence of benefit on all-cause death and confirmed that the safety profile is population-dependent. Separately, the 2023 Cochrane stroke update and prior dementia evidence together document a statistically significant increase in non-fatal serious adverse events in the cerebrolysin group in dementia populations (RR 2.39, 95% CI 1.10-5.23; 3 trials, N=1,335), with the 30 mL/10-day dose reaching RR 2.87 (95% CI 1.24-6.69). This SAE signal is incompatible with any confidence of benefit in this population.

Cochrane Library - Cerebrolysin for Vascular Dementia, Cui 2019 (PMID 31710397) ↗

Reduces microglial activation and neuroinflammation

In vitro and animal data support anti-inflammatory and neuroprotective effects via BDNF/NGF receptor mimicry. Mechanistic plausibility is established; direct causal evidence in humans is not. Note: this study originates from the EuroEspes Biomedical Research Center (Alvarez XA, Cacabelos R, et al.), a lab with documented ties to EVER Pharma (the cerebrolysin manufacturer) and co-author networks with research integrity concerns. The study itself has not been retracted, but its institutional provenance and funder proximity should be weighed when using it as a mechanistic anchor.

PubMed 10961440 - Cerebrolysin reduces microglial activation in vivo and in vitro (Alvarez et al., EuroEspes Biomedical Research Center, 2000) ↗

Safe with adverse event profile similar to placebo in controlled trials

Meta-analysis of 12 RCTs (N=2,202) found no statistically significant difference in adverse events vs. placebo in stroke trials. However, this safety finding is population-specific: a 2023 Cochrane update found a statistically significant increase in non-fatal serious adverse events in dementia populations (RR 2.39, 95% CI 1.10-5.23), rising to RR 2.87 at 30 mL/10-day dosing. The B-level safety finding for stroke patients should not be generalized to dementia or healthy populations. Absolute contraindications include epilepsy and porcine allergy. Rare seizure reports exist, causality not established.

PMC8708612 - Safety Meta-Analysis 12 RCTs (stroke population only), 2021 ↗

Prove it

Can you tell if it's working?

The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.

Not trackable

No objective self-tracker exists: cerebrolysin's only human-validated efficacy readouts are clinician-administered cognitive/functional scales (ADAS-cog, NIHSS, Barthel, mRS), not any blood, urine, wearable, scan, or CGM you can run yourself.

Bloodwork

No blood proxy

Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.

Cerebrolysin is a porcine brain-derived neuropeptide mixture that acts centrally by mimicking neurotrophic factors (BDNF/NGF/GDNF/CNTF) on CNS neurons; its therapeutic action is a neurological/cognitive effect that leaves no fingerprint on any routine peripheral blood analyte.

Read this before you spend on labs

Routine bloodwork cannot confirm cerebrolysin is working. Its effect is neurological and cognitive, and in every clinical trial efficacy is measured by functional/neurorecovery scales (NIHSS, modified Rankin, Barthel Index, GOS, MMSE, ADAS-cog), not labs. The only mechanism-relevant biomarker would be a central neurotrophin like serum BDNF, which is a research-only assay, not orderable at LabCorp/Quest, and not a validated human efficacy proxy anyway. No CBC, CMP, hormone, or other standard panel analyte moves in a way that reflects the drug's biological action, so a user cannot prove response through blood. Track subjective/functional cognitive or neurorecovery outcomes instead.

Bottom line

Cerebrolysin's claimed benefit is neurological recovery and cognition, and cognition has no validated objective proxy in any consumer modality. In trials the effect is captured only by clinician-scored scales (ADAS-cog+, NIHSS, modified Rankin, Barthel, MMSE) administered in controlled settings, and even there the stroke functional-independence endpoint has not reliably reached significance. With blood tier=none, there is genuinely nothing physiologic to track: no urine metabolite, stool marker, sleep/HRV signature, glucose pattern, VO2max change, DEXA change, or gene test reflects whether it is working, and serum BDNF is research-only and non-specific, not a validated proxy. A wearable will not show it. The most honest self-test is a blinded, placebo-controlled trial-of-one using a validated computerized cognitive battery (e.g., Cambridge Brain Sciences/CANTAB) with pre/post scores, but this is effort-dependent, high-placebo-risk, not a physiologic modality, and does not constitute objective biological verification. Treat any perceived benefit as unconfirmed.

Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.

How to track it →

Mechanism

How it's assumed to work

BBB penetration

Cerebrolysin is an enzymatic hydrolysa

Neurotrophic factor mimicry

Peptide fragments are proposed to mimi

Anti-apoptotic signaling

PI3K/Akt pathway activation is assumed

Microglial modulation (disputed)

Reduction of microglial activation and

Assumed · theoretical pathway

Assumed (mechanistic plausibility, not proven causal chain in humans). Cerebrolysin contains low-molecular-weight peptide fragments (all under 10 kDa) that are proposed to cross the blood-brain barrier and mimic endogenous neurotrophic factors including BDNF, NGF, GDNF, and CNTF. Proposed downstream effects include activation of TrkB and TrkA receptors, PI3K/Akt and MAPK/ERK pathway signaling, inhibition of caspase-3 (apoptosis), upregulation of Bcl-2 (anti-apoptotic), and reduction of microglial activation. Whether these mechanisms are operative in healthy brains at community-level doses is not established. Caution: a substantial portion of the preclinical mechanistic evidence was produced by Eliezer Masliah and Hari Shanker Sharma, both of whom have papers under active retraction and data integrity review as of 2025.

Dosing & handling

What users and clinicians report

Reported, not prescribed

Community-reported range: 5-10 mL IM (intramuscular) daily for 10-20 day courses, repeated 2-4x per year. Clinical trials used 30 mL IV infusion daily for 10-21 days in stroke/TBI. Some nootropic users report 2-5 mL SC (subcutaneous) though SC is not a studied route.

Reported doses are from community use, not prescriptions. The biggest dosing risk is route confusion: doses above 10 mL require IV infusion diluted in saline over 15-60 minutes. Self-administering IV infusions outside a clinical setting carries risk of air embolism, phlebitis, and severe allergic reaction with no immediate medical response available. Gray-market vials have no manufacturing quality guarantee.

Timing & food

Clinical trials administered IV infusions daily in the morning over 10-21 day blocks. No pharmacokinetic basis exists for specific timing in healthy-user protocols. Community practice varies widely (morning only, split AM/PM) without evidence basis.

Half-life

Not well characterized in humans. The peptide mixture is heterogeneous; individual fragments likely have half-lives ranging from minutes to a few hours. IV infusion achieves peak CNS levels during administration; IM half-life estimates are extrapolated, not directly measured.

Reconstitution sensitivity

Not reconstituted. Cerebrolysin is supplied as a ready-to-use aqueous solution (1 mL, 2 mL, 5 mL, 10 mL, 20 mL ampoules at 215.2 mg/mL). Requires refrigeration (2-8 degrees C). Gray-market sources may have cold-chain gaps that degrade the peptide mixture.

Real-world signal

What people actually report

Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.

Moderate signal· A real body of reports, fairly consistent.

Volume

High volume of community reports, primarily from Eastern European and Russian nootropic communities where Cerebrolysin is legally available and inexpensive. Growing Western nootropic interest since 2020.

Consistency

Mixed. Subjective reports of improved focus, mood, and verbal fluency are common but inconsistent. A subset reports agitation, headache, and no noticeable effect. TBI/stroke recovery anecdotes tend to be more positive and consistent than healthy-user reports.

Source credibility

Low for healthy-user enhancement claims. The community signal reflects a drug being used far outside its studied population (acute neurological injury) at doses below clinical trials. Hard to separate from expectation effects.

Anecdote: Eastern European and Russian users report improved verbal fluency and recall after 10-day IV courses, often at clinical doses (10-20 mL); effect described as arriving 2-3 days into the course and fading within 4-6 weeks post-cycle
Anecdote: A subset of users report agitation, irritability, and disrupted sleep during the active dosing window, especially at higher doses, consistent with the neurostimulatory profile seen in trials
Anecdote: Nootropic community users doing IM self-injection at 5 mL report subtler effects than IV users, with some reporting no noticeable change; the IV-vs-IM gap in perceived effect is a recurring theme
Anecdote: TBI and post-concussion users report the most consistent and pronounced subjective benefit; healthy-brain users are the most split, with a vocal minority reporting nothing and attributing prior reports to placebo

Placebo risk, High

Most wellness and cognitive enhancement endpoints are subjective (focus, mental clarity, mood). The ritual of IV or IM injection and the drug's exotic porcine-brain origin create strong expectation effects. Clinical trials in stroke/TBI used objective functional scales (NIHSS, GCS, GOS), which are absent in self-experimenter use.

Risk panel

What could go wrong

Adverse events

Generally mild in acute stroke controlled trials. Most common: dizziness, agitation, feeling hot, injection site reactions, mild headache, nausea. Adverse event incidence statistically similar to placebo in stroke meta-analyses (N=2,202). Critical population-specific warning: the 2023 Cochrane data in dementia populations found a statistically significant ~2.4x increase in non-fatal serious adverse events (RR 2.39, 95% CI 1.10-5.23; 3 trials, N=1,335), with the 30 mL/10-day protocol showing RR 2.87. The safety profile cannot be uniformly assumed across populations.

Theoretical concerns

Porcine-derived proteins carry a theoretical prion contamination risk, though manufacturing processes (enzymatic hydrolysis + filtration) are designed to eliminate this. Seizure threshold lowering is a documented concern.

Contraindications

Absolute: epilepsy or history of grand mal convulsions (may increase seizure frequency), porcine allergy, severe renal impairment. Not recommended in pregnancy. The 2023 Cochrane data in dementia populations documents a statistically significant increase in non-fatal serious adverse events that is absent from the stroke population, meaning dementia patients should be considered a distinct and higher-risk group.

Honest unknowns

Long-term effects of repeated cycling in healthy individuals are unstudied. The complex mixture contains hundreds of uncharacterized peptide fragments; batch variation between manufacturers (especially gray-market sources) is a real concern. No human pharmacokinetic data on IM vs. IV bioavailability equivalence.

Confound watch

Heavily stacked in nootropic communities with racetams, semax, selank, and other neuropeptides, making attribution impossible. Many users are also on TRT or GLP-1 agonists; improved cognitive clarity on either of those baselines is commonly misattributed to Cerebrolysin. Clinical trial benefits occurred in acute injury patients, not healthy individuals.

History

Discovery → first use → status

1949Developed by Professor Eberhard Windisch at the University of Vienna as a porcine brain-derived extract for treating TBI and metabolic brain failure in post-war Austria
1954First approved for clinical use in Austria; EBEWE (later EVER Neuro Pharma) industrialized production in the 1970s and standardized batch-to-batch consistency
1980s-1990sGained regulatory approval across Russia, Eastern Europe, China, and Asian nations; now approved in 45+ countries for stroke, TBI, and dementia
2019Cochrane review on vascular dementia described evidence as promising but low-certainty; FDA never approved it for any indication in the US, though orphan drug designation was granted for frontotemporal dementia investigation
2023-2025NIH found that Eliezer Masliah, former head of the Division of Neuroscience at the National Institute on Aging, committed research misconduct (data fabrication and falsification) across 130+ papers published 1997-2023. Masliah received EVER Pharma funding for multiple cerebrolysin studies and co-authored with Herbert Moessler (former EVER Pharma general manager, 19 papers flagged). Multiple cerebrolysin preclinical papers by Masliah and collaborator Hari Shanker Sharma were retracted by 2025, including a BMC Neuroscience paper on Pick's disease (retraction note PMID 40065222). The scope of affected preclinical cerebrolysin literature is actively under review as of 2025.

Verification

The COA standard, applied

Grade adversarially re-reviewed 2026-06-21 and downgraded to reflect the absence of formal human safety/efficacy data. Citations corrected 2026-06-22: (1) stroke claim basis updated to disclose that the mRS functional independence primary endpoint did not reach significance (RR 1.31, p>0.05) and that NIHSS 1.39 points is sub-threshold for NINDS MCID; (2) TBI claim basis updated to disclose mixed RCT/observational study design; (3) safety claim downgraded from B to C and split to reflect population-specific SAE finding in dementia cohorts (Cochrane RR 2.39); (4) microglial citation updated to disclose EuroEspes/EVER Pharma institutional ties; (5) research integrity disclosure added to risk section and mechanism section covering Masliah/Sharma misconduct and EVER Pharma funding; (6) 2023-2025 research misconduct history entry added; (7) 2023 Cochrane ischaemic stroke update and For Better Science/BMC retraction notice added to verification sources.

The full verification standard →

Sources

Where this comes from

PMC12465088 - Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: 14 RCT Meta-Analysis (2025) ↗· Most comprehensive stroke meta-analysis available as of 2025; pooled N=2,884; NIHSS improvement 1.39 points (significant); mRS 0-2 functional independence RR 1.31 (NOT significant, p>0.05); notes industry funding limitations. NIHSS improvement is sub-threshold for NINDS MCID of 4+ points.
Cochrane Library - Cerebrolysin for Vascular Dementia (Cui 2019, PMID 31710397) ↗· Cochrane systematic review; low to very low certainty overall; 6 RCTs N=597; major concerns about industry funding and study heterogeneity
PMC10046100 - Cerebrolysin in TBI: Systematic Review and Meta-Analysis (2023) ↗· 10 clinical studies (prospective and retrospective mixed design, not all blinded RCTs) N=8,749; significant GCS/GOS improvement; mortality not affected. Mixed study design should be weighted when interpreting pooled results.
PMC8708612 - Safety of Cerebrolysin for Ischemic Stroke: 12 RCT Meta-Analysis (2021) ↗· Safety-focused meta-analysis N=2,202 stroke patients; adverse events not significantly different from placebo in this population. Does not cover dementia or healthy-user populations where a separate Cochrane update found increased serious adverse events.
Cochrane Library - Cerebrolysin for Acute Ischaemic Stroke, Ziganshina 2023 (CD007026.pub7) ↗· 2023 Cochrane update; no evidence of mortality benefit; confirms the population-specific safety divergence between stroke and dementia cohorts.
For Better Science - Cerebrolysin: Sharmas, Masliah, and EVER Pharma (October 2024) ↗· Investigative documentation of research misconduct findings, EVER Pharma funding ties, and the scope of cerebrolysin preclinical papers affected by the Masliah/Sharma data integrity crisis.
BMC Neuroscience Retraction - Cerebrolysin Pick's disease paper (Masliah et al., PMID 40065222) ↗· Retraction notice for a cerebrolysin preclinical paper retracted in 2025 due to fabricated/re-used figure panels. One of multiple Masliah cerebrolysin retractions.

The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.